中国肝脏病杂志(电子版)

位置：首页 >> 期刊文章

外周血miRNA-26a的表达对经TACE治疗的原发性肝癌患者预后的意义

作者：纪民林海燕赵旭蒲春文李本科张骐麒宋瑞金姜伯昭

单位：大连市第六人民医院介入治疗科辽宁大连 116039

分类号：

出版年,卷(期):页码：2017,9(3):85-89

摘要：

摘要：目的探讨外周血miRNA-26a的表达对TACE治疗的原发性肝癌患者预后的意义。方法选取2013
年5月至2013年10月于本院行TACE治疗的原发性肝癌患者29例（A组）、代偿期肝硬化患者30例（B
组）及健康体检者30例（C组）为研究对象，采用实时定量PCR技术检测外周血miRNA-26a的表达水
平，分析原发性肝癌（PLC）患者TACE治疗术后miRNA-26a表达水平的变化、不同miRNA-26a表达
水平的PLC患者无疾病进展时间（progress free survival，PFS）及1、2、3年生存率的差异。结果肝癌
患者外周血miRNA-26a的表达水平（1.230 ± 0.299）低于代偿期肝硬化组（1.897 ± 0.534）和健康体检
组（2.427 ± 0.569），差异有统计学意义（t = -5.542、 -10.058，P ＜ 0.001）；原发性肝癌患者TACE
治疗前后外周血miRNA-26a表达水平的差异有统计学意义[（1.230± 0.299）vs （2.154 ± 0.371），t =
-8.786，P ＜ 0.001）。以TACE术前外周血miRNA-26a表达的中位值1.145将PLC患者分为高表达组（13
例）和低表达组（16例），高表达组的无疾病进展生存时间为（27.18 ± 4.28）个月，显著高于低表达
组的（17.23 ± 9.18）个月，差异有统计学意义（t = 5.287，P = 0.019），高表达组1、2、3年生存率分
别为92.31 %、76.92%和61.54%，低表达组的1、2、3年生存率分为93.75%、50.00%、43.75%，差异有
统计学意义（χ 2 = 3.885，P = 0.032）。结论原发性肝癌患者经TACE治疗后外周血miRNA-26a的表达水
平提高，外周血miRNA-26a的表达对原发性肝癌介入治疗的预后评估有判断价值。

Abstract: Objective To investigate the prognostic significance of miRNA-26a expression in peripheral
blood in patients with primary liver cancer who were treated with transcatheter arterial chemoembolization
(TACE). Methods Total of 29 cases with primary liver cancer who underwent TACE (group A), 30 cases
with decompensated cirrhosis (group B) and 30 healthy controls (group C) in our hospital from May 2013
to October 2013 were selected. The expression levels of peripheral plasma miRNA-26a were detected by
real-time quantitative PCR. The changes of miRNA-26a expression in patients with primary liver cancer
(PLC) after TACE treatment were analyzed. The time without disease progression (PFS) and 1, 2 and 3 year
survival rates of PLC patients with different miRNA-26a expression levels were also analyzed. Results The
expression level of miRNA-26a in peripheral blood of patients with hepatocellular carcinoma (1.230 ± 0.299)
was lower than those in compensated cirrhosis group (1.897 ± 0.534) and healthy controls (2.427 ± 0.569),
the differences were statistically significant (t = -5.542, -10.058; P ＜ 0.001). The difference of expression
level of miRNA-26a in peripheral blood in patients with primary liver cancer before and after TACE was
statistically significant [(1.230 ± 0.299) vs (2.154 ± 0.371)，t = -8.786, P ＜ 0.001]. Patients with PLC
were divided into miRNA-26a high expression group and low expression group according to the median of

miRNA-26a 1.145. PFS in miRNA-26a high expression group [(27.18 ± 4.28) months] was significantly
higher than that in miRNA-26a low expression group [(17.23 ± 9.18) months], the difference was statistically
significant (t = 5.287, P = 0.019). The survival rates of 1, 2 and 3 year in miRNA-26a high expression group
were 92.31%, 76.92% and 61.54%, respectively. The survival rates of 1, 2 and 3 year in miRNA-26a low
expression group were 93.75%, 50.00% and 43.75%, respectively. The difference was statistically significant
(t = 3.885, P = 0.032). Conclusions TACE can improve the expression level of miRNA-26a in peripheral
blood of patients with primary liver cancer, and the expression of miRNA-26a in peripheral blood can be
used to evaluate the prognosis of primary liver cancer.

基金项目：

作者简介：

参考文献：

服务与反馈：

【文章下载】【加入收藏】